RxDoctor Payments Data

Harold Blackmon

Family · Opelika, ALNPI 1639792955

Payments from drug & device makers

$3,511in general payments, 2019–2025

Across 112 payments — averaging $31.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$463
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$439
  • Merck$364
  • Inspire Medical Systems, Inc.$304
  • Medtronic$252
  • Lexicon Pharmaceuticals, Inc.$236
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,511100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,511 in reported general payments places this provider in the 85th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$80,878
Medicare patients
447
Services billed
844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban597$478,037
EntrestoSacubitril/Valsartan182$186,663
BrilintaTicagrelor69$45,958
FarxigaDapagliflozin Propanediol60$41,709
XareltoRivaroxaban27$18,151
Metoprolol Succinate573$12,032
LivaloPitavastatin Calcium16$11,444
VascepaIcosapent Ethyl18$6,299
Repatha SyringeEvolocumab14$4,640
SotalolSotalol Hcl161$3,637
Valsartan66$3,394
Ranolazine ErRanolazine36$3,356
Losartan Potassium265$2,787
ClopidogrelClopidogrel Bisulfate215$2,749
Atorvastatin Calcium222$2,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$478,037597 claims
NovartisEntresto$126$186,663182 claims
AstraZenecaBrilinta, Farxiga$463$87,667129 claims
Johnson & JohnsonXarelto$107$18,15127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,415 family providers in Alabama.

Other family in Opelika

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →